Clinical Risk Factors and Evaluation Framework Before starting any GLP-1 medication, your provider should assess personal history of pancreatitis, inflammatory bowel disease, severe gastroparesis, chronic diarrhea, and family history of medullary thyroid carcinoma
When mitochondrial glutathione becomes depleted, oxidative damage accelerates at the primary site of ROS generation
If it appears yellow, brown, or has visible moisture inside the sealed vial, do not use it
Never inject the exact same spot on consecutive days
A synergistic action in which glucagon receptor activation enhances energy expenditure whilst GLP-1 receptor agonists reduce calorie intake and both GLP-1/GIP potentiate the incretin effect to modulate the diabetogenic effect of glucagon agonists
10.1007/s00421-011-2246-z 155 WhiteJ